ArticleComprehensive psychoneuroendocrinology2026
The effect of gender-affirming hormonal treatment on personality traits
Article in Comprehensive psychoneuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gender-affirming hormone therapy is a crucial component of the medical transition for many transgender individuals. While there are well-established differences in personality traits between cisgender men and women, the effects of gender-affirming hormone therapy on these traits in transgender individuals remain largely unexplored. Aims: The primary aim of this study was to investigate whether gender-affirming hormone therapy affects personality traits in transgender individuals. Materials and methods: Adult transgender persons referred for gender-affirming hormone therapy to ANOVA, Center for Andrology, Sexual Medicine, and Trans Medicine at Karolinska University Hospital, Stockholm, Sweden, completed the NEO-PI-R inventory once before starting hormone therapy and once after a minimum of six months of either anti-androgen and estradiol treatment or testosterone therapy. Changes in scores were analyzed using the Wilcoxon Signed-Ranks Test. Patients who had any known hormonal, chromosomal, psychiatric, neurological, or other major medical disorders were excluded from the study. Results: At baseline, the assigned female at birth (AFAB) had significantly higher NEO-PI-R scores in the dimension "Agreeableness" and the facets E5 "Excitement seeking" and A2 "Straightforwardness" compared to the assigned male at birth (AMAB). With treatment, the AMAB showed an increase in O3 "Feelings" (md = 2.00; IQR = 0.00-11.50; Conclusions: Few changes in personality traits were observed, but they aligned with expectations based on established sex differences in personality traits. In general, more changes were observed in the testosterone treated group. The reduction in "Neuroticism" and "Vulnerability" in the AFAB with treatment, but a worsening or no change in the AMAB may be concerning. Further studies are needed to solidify these results and explore the underlying causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.